

PCT

Report of EP 04 74 9467.9  
Your Ref.: H&P 110.02150301  
WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : A61K 38/00, A01N 37/18		A1	(11) International Publication Number: WO 97/35601
			(43) International Publication Date: 2 October 1997 (02.10.97)
(21) International Application Number: PCT/US97/04887		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 26 March 1997 (26.03.97)			
(30) Priority Data: 08/621,629 26 March 1996 (26.03.96) US			
(71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 22nd floor, 300 Lakeside Drive, Oakland, CA 94612-3550 (US).			
(72) Inventor: WOO, David, D., L.; 10442 Colina Way, Los Angeles, CA 90077 (US).		Published With international search report.	
(74) Agent: ALTMAN, Daniel, E.; Knobbe, Martens, Olson and Bear, 16th floor, 620 Newport Center Drive, Newport Beach, CA 92660 (US).			

(54) Title: TREATMENT OF CYSTIC DISEASE WITH TNF- $\alpha$

Survival of TNF- $\alpha$  treated CPK mice



(57) Abstract

A method for treating polycystic kidney disease in an individual in need thereof. This method includes identifying a mammal having a cystic disease and administering to the mammal a pharmacologically effective anticystic amount of TNF-alpha or an agent which stimulates TNF-alpha production *in vivo*. The agent is administered in a pharmacologically acceptable carrier, excipient or diluent.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CN	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

TREATMENT OF CYSTIC DISEASE WITH TNF- $\alpha$ Field of the Invention

The present invention relates to treatment of cystic diseases. More specifically, the invention relates to treatment of polycystic kidney disease by administration of TNF- $\alpha$  or agents which stimulate production of TNF- $\alpha$ .

Background of the Invention

There are many human diseases which result in the formation of cysts which contain either semi-solid or fluid material. The contents of a cyst sometimes derive from normally retained fluid (e.g. a sebaceous cyst can contain fluid from a blocked sebaceous gland) or from a parasitic infection. Benign cysts can occur in the ovary, spleen, lungs, kidney and liver, where they are often congenital. Some congenital cysts result from fetal malformations and developmental failure while others are direct results of a disease state.

The polycystic kidney diseases (PKD) are a group of disorders characterized by the presence of a large number of fluid-filled cysts throughout grossly enlarged kidneys (Gabow et al., *Diseases of the Kidney*, Schrier et al. eds., 1992). In humans, PKDs can be inherited in autosomal dominant (ADPKD) or autosomal recessive (ARPKD) forms. ADPKD is the most common, dominantly-inherited kidney disease in humans, occurring at a frequency of about 1 in 800. ARPKD occurs at a frequency of about 1 in 10,000. Clinically, PKD represents a major cause of end-stage renal disease. Microdissection, histochemical and immunologic studies show that cysts in ARPKD kidneys arise from focal dilations of medullary collecting ducts (McDonald, *Semin. Nephrol.*, 11:632-642, 1991). Mutations in at least three different loci have been associated with ADPKD in humans, including PKD1 on chromosome 16, PKD2 on chromosome 4, and the not yet mapped PKD3 (Reeders et al., *Nature*, 317:542-544, 1985; Kimberling et al., *Genomics*, 18:467-472, 1993; Daoust et al., *Genomics*, 25:733-736, 1995). The ARPKD mutation is found on human chromosome 6 (Zerres et al., *Nature Genet.*, 7:429-432, 1994). The molecular mechanisms leading to cyst enlargement and progressive loss of renal function in PKDs are not completely understood. Besides dialysis and transplantation, which are palliative, there are no preventive or curative treatment for PKDs.

In 1977, it was reported that a recessive congenital polycystic kidney (*cpk*) disease arose spontaneously in C57BL/6J mice (Preminger et al., *J. Urol.*, 127:556-560, 1982). The *cpk* mutation has been mapped to mouse chromosome 12 (Davisson et al., *Genomics*, 9:778-781, 1991). Kidney maldevelopment and progression of PKD in C57BL/6-*cpk/cpk* mice have been characterized in detail (Preminger, *ibid.*; Mandell et al., *Am. J. Pathol.*, 113:112-114, 1983). Affected animals appear normal at birth and have microscopic dilations of their proximal renal tubules. These enlarged tubules develop into cysts. At 10-13 days of age, homozygous *cpk/cpk* animals may be recognized by protuberant abdomens resulting from greatly enlarged kidneys. After day 10-12, additional cysts develop rapidly from dilations of medullary collecting ducts. Consequently, the kidneys rapidly enlarge, reaching almost 2.0 g in kidney weight at day 24 compared to about 0.18 g for age-matched normal kidneys. Cystic expansion is accompanied by the apoptotic loss of non-cystic nephrons (Woo, *New Engl. J. Med.*, 333:18-25, 1995). Concomitant with kidney enlargement, there is a gradual decrease in kidney function with blood urea nitrogen (BUN) reaching 120 mg/dL by 24 days of age. Polycystic mice become progressively lethargic and die by 28-35 days of age due to renal failure.

Hallmark features of cystic changes in human PKD epithelia such as cellular hyperplasia and abnormal basement membrane are observed in *cpk* cysts at both the light and electron microscopic level (Gattone et al., *Am. J. Kidney Dis.*, 17:606-607, 1991). The accumulation of fluid in cysts indicates abnormal fluid transport in *cpk* cystic epithelia. The presence of altered expression of basement membrane (Taub et al., *Kidney Int.*, 37:1090-1097, 1990; Ebihara et al., *Lab. Invest.*, 58:262-269, 1988), altered growth-controlling gene expression (Horikoshi et al., *Kidney Int.*, 39:57-62, 1991; Gattone et al., *Dev. Biol.*, 138:225-230, 1990; Cowley et al., *J. Am. Soc. Nephrol.*, 1:1048-1053, 1991), altered targeting of the normally basolaterally sodium-potassium ATPase and EGF receptor (Avner et al., *Proc. Natl. Acad. Sci. U.S.A.*, 89:7447-7451, 1992; Orellana et al., *Kidney Int.*, 47:490-499, 1995), and expression of developmentally dedifferentiated phenotypes (Harding et al., *Dev. Biol.*, 146:483-490, 1991) make the *cpk* mouse a useful animal for studying the diverse renal pathobiologies of PKD. The overall progression of PKD is very similar in the *cpk* mouse and in humans.

The microtubule-specific drug taxol significantly inhibits the progression of PKD and significantly prolongs the survival of polycystic *cpk* mice (Woo et al., *Nature*, 368:750-753, 1994; PCT W094/08041). Instead of dying of azotemia by four to five weeks of age, polycystic mice treated weekly with taxol can survive to more than six months of age. Taxol binds to microtubules and inhibits microtubule depolymerization. Accordingly, the microtubule cytoskeleton has been postulated to play a role in pathogenesis of PKD in the *cpk* mouse. In addition to its microtubule stabilizing effects, taxol specifically induces the expression of tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) in macrophages and lymphocytes. The ability of taxol to induce production of TNF- $\alpha$  is not shared by other members of the taxane family.

TNF- $\alpha$  is a pleiotropic cytokine that mediates diverse cellular responses including cytotoxicity, cytostasis, proliferation, differentiation and the expression of specific genes (Beutler et al., *Science*, 264:667-668, 1994). TNF- $\alpha$  is cytotoxic for a wide variety of tumor cells, but only toxic to a few selected normal cell types (Carswell et al., *Proc. Natl. Acad. Sci. U.S.A.*, 72:3666-3670, 1975; Tsujimoto et al., *Proc. Natl. Acad. Sci. U.S.A.*, 82:7626-7630, 1985). Despite the presence of cell surface TNF- $\alpha$  receptors, the majority of normal mammalian cells are resistant to the cytotoxic effects of TNF- $\alpha$  (Tsujimoto et al., *ibid.*). In addition, TNF- $\alpha$  is protective against apoptotic cell death in several cell types (Wong et al., *Science*, 242:941-944, 1988; Mangan et al., *J. Immunol.*, 146:1541-1546, 1991; Warner et al., *Am. J. Physiol.*, 260:L296-L301, 1991).

Thus, there is a need for a therapeutic agent capable of treating cystic disease. The present invention satisfies this need.

30

#### Summary of the Invention

One embodiment of the present invention is the use of TNF- $\alpha$  or an agent which stimulates TNF- $\alpha$  production *in vivo*, with the proviso that said agent is not taxol, in the preparation of a medicament for treatment of cystic disease. Preferably, the agent is indomethacin, naproxen, ibuprofen, tenidap or imiquod. According to one aspect of this preferred embodiment, the cystic disease is breast cysts, bronchogenic cysts, choledochal cysts, colloidal cysts, congenital cysts, dental cysts, epidermoid inclusions, hepatic cysts, hydatid cysts, lung cysts, mediastinal cysts, ovarian cysts, periapical cysts, pericardial cysts or polycystic kidney disease. In a particularly

35

preferred embodiment, the cystic disease comprises polycystic kidney disease. Preferably, the medicament is in a form suitable for intravenous, intraperitoneal, intraarterial, subcutaneous, oral or intramuscular administration.

Another embodiment of the invention is a method of treating a mammal having a cystic disease, comprising the step of administering to the mammal a pharmacologically effective anti-cystic amount of TNF- $\alpha$  or an agent which stimulates TNF- $\alpha$  production *in vivo*, with the proviso that said agent is not taxol, the agent being administered in a pharmacologically acceptable carrier, excipient or diluent. Preferably, the mammal is a human. In one aspect of this preferred embodiment, the cystic disease is breast cysts, bronchogenic cysts, choledochal cysts, colloidal cysts, congenital cysts, dental cysts, epidermoid inclusions, hepatic cysts, hydatid cysts, lung cysts, mediastinal cysts, ovarian cysts, periapical cysts, pericardial cysts or polycystic kidney disease. Preferably, the cystic disease comprises a polycystic kidney disease. Advantageously, the administering step is selected from the group consisting of intravenous, intraperitoneal, intraarterial, subcutaneous, oral and intramuscular administration. More advantageously, the administering step is intravenous.

#### Brief Description of the Drawings

Figure 1 shows the survival of taxol-treated polycystic *cpk* mice. The number of days after taxol or placebo treatment is shown on the x-axis and the survival rate is shown on the y-axis.

Figure 2 shows the survival of TNF- $\alpha$  treated *cpk* mice. The number of days after TNF- $\alpha$  or placebo treatment is shown on the x-axis and the cumulative survival is shown on the y-axis.

#### Detailed Description of the Preferred Embodiment

The present invention provides a method of treating PKD by administration of TNF- $\alpha$  or an agent which stimulates the production of TNF- $\alpha$ . Although the treatment of PKD is exemplified herein, the treatment of any cystic disease is within the scope of the invention. Such cystic diseases include breast cysts, bronchogenic cysts, choledochal cysts, colloidal cysts, congenital cysts, dental cysts, epidermoid inclusions, hepatic cysts, hydatid cysts, lung cysts, mediastinal cysts, ovarian cysts, periapical cysts, pericardial cysts or polycystic kidney disease.

TNF- $\alpha$  or an agent which stimulates TNF- $\alpha$  production may be administered by various routes, including intravenously, intraperitoneally, intramuscularly, intra-arterially, subcutaneously, orally or in any other appropriate way known in the art in a pharmaceutically acceptable carrier, excipient or diluent. TNF- $\alpha$  for parenteral administration may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to methods well known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a parenterally acceptable diluent or solvent, such as a solution in 1,3-butanediol. Suitable diluents include, for example, water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile fixed oils may be employed conventionally as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid may likewise be used in the preparation of injectable preparations.

The tolerated dose of recombinant TNF- $\alpha$  in phase I clinical trials is 150,000 units/kg (Bollon et al., *J. Cell. Biochem.*, 36:353-367, 1988). The preferred effective dose range of TNF- $\alpha$  for treatment of human cystic diseases

is between about 50,000 units/kg and 150,000 units/kg; a more preferred dose is between about 75,000 units/kg and about 125,000 units/kg; a most preferred dose is about 100,000 units/kg. This treatment is typically repeated every two or three days until a significant improvement in the cystic disease is observed. TNF- $\alpha$  can be administered either before a cyst has formed, to prevent its formation, or after a cyst has already been detected.

5 In addition, agents which stimulate TNF- $\alpha$  production are also useful in treating cystic diseases. Such agents include, for example, the non-steroidal anti-inflammatory drugs indomethacin, naproxen and ibuprofen (*Drugs Exp. Clin. Res.*, 19:243-248, 1993), tenidap (Golding et al., *J. Immunol.*, 154:5384-5390, 1995), a synthetic low-toxicity lipid A analog (Akimoto et al., *Int. J. Immunopharmacol.*, 16:887-893, 1994) and imiquod (*J. Leukoc. Biol.*, 55:234-240, 1994). The ability of such compounds to treat cystic diseases may be determined by one of ordinary  
10 skill in the art using the mouse *cpk* polycystic kidney disease model as described in Example 1 for TNF- $\alpha$  and taxol treatment.

#### Example 1

##### TNF- $\alpha$ and taxol treatment of *cpk* mice

Heterozygous C57BL/6-*cpk*/+ breeder mice were obtained from the Jackson Laboratory (Bar harbor, ME).  
15 The *cpk* mouse colony was maintained by mating known heterozygotes. Mice were kept with their mothers until they were weaned at 28 days of age.

Taxol obtained from the Drug Synthesis and Chemistry Branch of the National Cancer Institute (Bethesda, MD) was dissolved at 10 mg/ml in dimethyl sulfoxide (DMSO) and stored at -20°C. Taxol treatment was initiated on 10 day old polycystic *cpk* mice diagnosed to be polycystic by the presence of palpably enlarged kidneys. Mice  
20 were injected intraperitoneally with 10  $\mu$ g of taxol per gram body weight on day 10 and 100  $\mu$ g taxol per animal on subsequent weeks. Polycystic mice treated with an equal volume of DMSO were used as controls.

Weekly taxol treatment clearly increased the survival rate of *cpk* mice (n=43) compared to control (carrier vehicle) treated mice (Figure 1). When weekly taxol treatment was initiated at 10 days of age, 60% of all polycystic mice survived past 40 days of age, while at this time, 80% of the untreated polycystic *cpk* mice had died. 35%  
25 of polycystic mice treated weekly with taxol lived past 90 days of age, while all polycystic *cpk* mice treated with DMSO died. Statistically, the difference in survival between control and taxol treated mice is highly significant (Log-rank chi-square=7.80 and p=0.005). The serum creatinine of three taxol treated polycystic *cpk* mice when sacrificed at 90 days of age was  $2.8 \pm 0.8$  mg/dL (vs. 6.0 mg/dL in untreated 24 day old mice).

Sterile recombinant murine TNF- $\alpha$  (1 mg/ml, Genentech, South San Francisco, CA) was stored at 4°C in  
30 phosphate buffered saline (PBS). Beginning on day 7 after birth, the entire litter of mice from selective matings was injected intraperitoneally with 2  $\mu$ l TNF- $\alpha$  every other day. After day 10, only mice with palpable polycystic kidneys continued to receive TNF- $\alpha$ . Polycystic mice identically treated with PBS were used as controls. All polycystic mice were continually treated for the duration of their life.

All TNF- $\alpha$  experiments were initiated on day 7 by administering TNF- $\alpha$  to the entire litter. Despite  
35 treatment, the kidneys of polycystic *cpk* mice treated with TNF- $\alpha$  on day 7 continue to enlarge and become palpable by day 10. The kidneys of mice without palpably enlarged kidneys by day 10 were all histologically normal. Figure

2 compares the survival of 21 polycystic *cpk* mice given 2  $\mu$ g TNF- $\alpha$  every other day and 25 polycystic *cpk* mice treated similarly with saline. Over 90% of TNF- $\alpha$  treated polycystic *cpk* mice survived past 40 days of age. In contrast, only 20% of the saline treated *cpk* mice survived beyond 40 days of age. Almost 50% of TNF- $\alpha$  treated mice survived past 100 days of age. In contrast, none of the saline-treated mice lived past 90 days of age.

5 Statistically, the difference in survival between control and TNF- $\alpha$  treated *cpk* mice is highly significant (Log-rank chi-square = 24.17 and  $p < 0.0001$ ). Because taxol is known to stimulate TNF- $\alpha$  production, the ability of taxol to inhibit the progression of PKD in polycystic *cpk* mice is due, at least in part, to this activity.

For histology studies, animals were sacrificed and their kidneys were fixed overnight in 10% neutral buffered formalin (Fisher Scientific, Pittsburgh, PA), dehydrated in ethanol, infiltrated and embedded in paraffin. Five micron

10 histological sections were prepared and stained with periodic acid-Schiff stain, counter stained with hematoxylin and visualized by light microscopy.

A striking contrast was observed between the tightly packed functional nephrons seen within the histological sections of normal mice and the apoptotic loss of non-cystic nephrons in the kidneys of polycystic mice. Direct comparison between normal mice and polycystic mice at 10 days of age revealed a loss of approximately 50% of

15 the non-cystic nephrons. Almost all of the remaining non-cystic nephrons were rapidly and completely lost during the next ten to fourteen days. By the third to fourth week after birth, only a few life sustaining neurons remained. during the three to four weeks of rapid progression to complete renal failure, no signs of tubular necrosis, interstitial inflammation or interstitial fibrosis were detected in the polycystic *cpk* kidneys.

Compared to kidneys obtained from a 28 day old azotemic polycystic *cpk* mouse, kidneys obtained from

20 apparently healthy polycystic *cpk* mice treated with TNF- $\alpha$  for 90 days were significantly smaller in size. Kidneys from TNF- $\alpha$  treated polycystic *cpk* mice appeared to be very similar to kidneys from polycystic *cpk* mice treated weekly with taxol for the same length of time by both gross and histological criteria. Both of these treated kidneys had far fewer and much smaller cysts than kidneys from untreated or saline treated polycystic *cpk* mice. Histological examination revealed the presence of a number of hypertrophied nephrons in kidneys from both the TNF- $\alpha$  and taxol

25 treated mice. Significant interstitial fibrosis was also observed in kidneys of both TNF- $\alpha$  and taxol treated mice. Both treated groups have kidneys with a large fluid filled central lumen which results from enlargement of the renal pelvis. This feature is most likely a result of the chronic renal disease state the treated mice experienced and not a result of the TNF- $\alpha$  or taxol treatment.

Renal function was assessed as described in the following example.

30

#### Example 2

##### Determination of Renal Function

Mice were sacrificed at the indicated age and 0.5 ml blood was collected from the aorta. Serum creatinine was measured in triplicate using a commercial creatinine kit (Sigma, St. Louis, MO) with the following modifications. Because hemolysis of serum strongly interfered with the creatinine assay, hemoglobin in serum samples (100  $\mu$ l) was

35 precipitated with trichloroacetic acid at a final concentration of 10%. Precipitated proteins were removed by centrifugation at 13,000 rpm for 10 minutes and the serum neutralized to pH 7.0. Creatinine determination was

performed with 25  $\mu$ l of the neutralized serum in flat-bottom rigid microtiter plates (Corning, Corning, NY) according to the creatinine assay kit instructions, but scaled down to a 250  $\mu$ l assay volume. Absorbance both before and after addition of the acid reagent was recorded at 490 nm using a Molecular Device VMax 96 well plate reader.

5 The average serum creatinine of three active polycystic mice treated with TNF- $\alpha$  was  $3.3 \pm 0.6$  mg/dl when they were sacrificed at 90 days of age.

Human cysts may be treated *in vivo* as described in the following example.

### Example 3

#### Treatment of Human Cysts

10 A subject having a cystic disease or at risk for developing a cystic disease is first identified. For example, a subject can be identified by a physician, who diagnoses that subject as having ADPKD. After identifying an appropriate subject for treatment, that subject is intravenously administered a pharmaceutically effective dose (e.g. 100,000 units/kg) of recombinant human TNF- $\alpha$ . TNF- $\alpha$  can be administered either before a cyst has formed, in order to prevent its formation, or after a cyst has already been detected in a subject. This administration is repeated, for example, every three days during the time the patient has or is susceptible to developing a cyst. In  
15 this way an effective amount of the compound can be maintained in the subject.

It should be noted that the present invention is not limited to only those embodiments described in the Detailed Description. Any embodiment which retains the spirit of the present invention should be considered to be within its scope. However, the invention is only limited by the scope of the following claims.




**WE CLAIM:**

1. Use of TNF- $\alpha$  or an agent which stimulates TNF- $\alpha$  production *in vivo*, with the proviso that said agent is not taxol, in the preparation of a medicament for treatment of cystic disease.
2. The use of Claim 1, wherein said agent is selected from the group consisting of indomethacin,  
5 naproxen, ibuprofen, tenidap and imiquod.
3. The use of Claim 1, wherein said cystic disease is selected from the group consisting of breast cysts, bronchogenic cysts, choledochal cysts, colloidal cysts, congenital cysts, dental cysts, epidermoid inclusions, hepatic cysts, hydatid cysts, lung cysts, mediastinal cysts, ovarian cysts, periapical cysts, pericardial cysts and polycystic kidney disease.
- 10 4. The use of Claim 3, wherein said cystic disease comprises polycystic kidney disease.
5. The use of Claim 1, wherein said medicament is in a form suitable for intravenous, intraperitoneal, intraarterial, subcutaneous, oral or intramuscular administration.
6. A method of treating a mammal having a cystic disease, comprising the step of administering to  
15 said mammal a pharmacologically effective anti-cystic amount of TNF- $\alpha$  or an agent which stimulates TNF- $\alpha$  production *in vivo*, with the proviso that said agent is not taxol, said agent being administered in a pharmacologically acceptable carrier, excipient or diluent.
7. The method of Claim 6, wherein said mammal is a human.
8. The method of Claim 6, wherein said cystic disease is selected from the group consisting of breast  
20 cysts, bronchogenic cysts, choledochal cysts, colloidal cysts, congenital cysts, dental cysts, epidermoid inclusions, hepatic cysts, hydatid cysts, lung cysts, mediastinal cysts, ovarian cysts, periapical cysts, pericardial cysts and polycystic kidney disease.
9. The method of Claim 8, wherein said cystic disease comprises a polycystic kidney disease.
10. The method of Claim 6, wherein said administering step is selected from the group consisting of intravenous, intraperitoneal, intraarterial, subcutaneous, oral and intramuscular administration.
- 25 11. The method of Claim 10, wherein said administering step is intravenous.


1/2

### Survival of Taxol Treated Polycystic *cpk* Mice



2/2

## Survival of TNF- $\alpha$ treated CPK mice



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US97/04887

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 38/00; A01N 37/18

US CL : 514/2

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/642

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
NoneElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Please See Extra Sheet.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 94/08041 A1 (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA) 14 April 1994 (14-04-94), page 2, lines 1-7	1-11
Y	WOO et al., Taxol inhibits progression of congenital polycystic kidney disease. Letters to Nature. 21 April 1994, Vol. 368, pp. 750-750.	1-11

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
*O* documents referring to an oral disclosure, use, exhibition or other means		
*P* documents published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

11 MAY 1997

Date of mailing of the international search report

08 JUL 1997

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

WAYNE C. JONES

Telephone No. (703) 308-1235

Form PCT/ISA/210 (second sheet)(July 1992)\*

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/04887

### B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

EMBASE, MEDLINE, CANCERLIT, HCAPLUS search terms: tumor necrosis factor alpha/ct, tumor necrosis factor  
?, kidney cys/ct or kidney polycystic disease/ct, kidney?, renal?, nephr?, lymphokin?/cw, cytokin?/cw, cystic or  
polycystic, ((tumor or tumors) () necrosis), atresia  
IFICDB (CLAIMS) search terms: tumor necrosis factor, taxol#, cystic(Sa)disease##, cyst#, tni##

